DDInter1266 DDInter484
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Naproxen {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Naproxen {u} (Compound) upregulates {v} (Gene) VAV3
VAV3 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Naproxen {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Naproxen {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Naproxen {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Almotriptan
Almotriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Naproxen {u} (Compound) upregulates {v} (Gene) VAV3
VAV3 {u} (Gene) interacts with {v} (Gene) PDGFRB
PDGFRB {u} (Gene) is bound by {v} (Compound) Dasatinib
Naproxen {u} (Compound) upregulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Naproxen {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is regulated by {v} (Gene) MAP3K3
MAP3K3 {u} (Gene) is bound by {v} (Compound) Dasatinib
Naproxen (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dasatinib (Compound)
Naproxen (Compound) upregulates VAV3 (Gene) and VAV3 (Gene) is upregulated by Dasatinib (Compound)
Naproxen (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Dasatinib (Compound)
Naproxen (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Dasatinib
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Flurbiprofen may lead to a major life threatening interaction when taken with Dasatinib
Naproxen (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Almotriptan (Compound) and Almotriptan may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Naproxen (Compound) upregulates VAV3 (Gene) and VAV3 (Gene) interacts with PDGFRB (Gene) and PDGFRB (Gene) is bound by Dasatinib (Compound)
Naproxen (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound)
Naproxen (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is regulated by MAP3K3 (Gene) and MAP3K3 (Gene) is bound by Dasatinib (Compound)